CookieStocks
MRNA beat EPS estimates by 129.8%. Quarter ended Sep 30, 2026. Beat estimates in 4 of the last 4 quarters.

2026-11-10 · MRNA

MRNA beat EPS estimates by 129.8%

Quarter ended Sep 30, 2026. Beat estimates in 4 of the last 4 quarters.

The story in plain words

Tuesday, November 10, 2026. MRNA beat EPS estimates by 129.8%. Quarter ended Sep 30, 2026. Beat estimates in 4 of the last 4 quarters.

What the data shows for Moderna (MRNA): EPS $0.38 vs a consensus estimate of $-1.28. EPS +174.5% vs the same quarter a year earlier. Revenue $1.3B, +29.2% vs a year earlier.

Worked out from that data: Beat estimates in 4 of the last 4 quarters.

About the company: Moderna trades as MRNA and is part of the S&P 500, in the Health Care sector (Biotechnology), headquartered in Cambridge, Massachusetts, founded in 2010.

This is one of CookieStocks’ daily stock stories about S&P 500 earnings reports: reported earnings per share against expectations, with the history behind them. Stories are found automatically each trading day from market data and SEC filings, and every claim is labelled as observed, calculated or a possible contributor. Statistics only, not investment advice.

Prove it

Every claim on the graphic, labelled: observed (straight from the data), calculated (worked out from it), or possible contributor (lines up in time, not a confirmed cause).

  • OBSERVED
    EPS $0.38 vs a consensus estimate of $-1.28Nov 6, 2026, 3:00 PM ET
  • OBSERVED
    EPS +174.5% vs the same quarter a year earlierSource: SEC EDGAR · Nov 6, 2026, 3:00 PM ET
  • OBSERVED
    Revenue $1.3B, +29.2% vs a year earlierSource: SEC EDGAR · Nov 6, 2026, 3:00 PM ET
  • CALCULATED
    Beat estimates in 4 of the last 4 quartersHow: count of quarters with EPS ≥ estimate

Moderna (MRNA) financials and filings →

More stories

Statistics only, not investment advice. Past moves don’t predict future ones. Data as of Nov 10, 2026, 4:35 PM ET.